Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) do not Increase the Risk of Hepatic Impairment in Patients with Non-Valvular Atrial Fibrillation: Insights from Multi-Source Medical Data

MLA

Zhi-Chun Gu, et al. “Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Do Not Increase the Risk of Hepatic Impairment in Patients with Non-Valvular Atrial Fibrillation: Insights from Multi-Source Medical Data.” Reviews in Cardiovascular Medicine, vol. 23, no. 3, Mar. 2022, p. 098. EBSCOhost, https://doi.org/10.31083/j.rcm2303098.

APA

Zhi-Chun Gu, Jia Wang, Chi Zhang, Bin Zhao, & Zhi-Ling Li. (2022). Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) do not Increase the Risk of Hepatic Impairment in Patients with Non-Valvular Atrial Fibrillation: Insights from Multi-Source Medical Data. Reviews in Cardiovascular Medicine, 23(3), 098. https://doi.org/10.31083/j.rcm2303098

Chicago

Zhi-Chun Gu, Jia Wang, Chi Zhang, Bin Zhao, and Zhi-Ling Li. 2022. “Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Do Not Increase the Risk of Hepatic Impairment in Patients with Non-Valvular Atrial Fibrillation: Insights from Multi-Source Medical Data.” Reviews in Cardiovascular Medicine 23 (3): 098. doi:10.31083/j.rcm2303098.